Technical Analysis for VNDA - Vanda Pharmaceuticals Inc.
|Grade||Last Price||% Change||Price Change|
VNDA closed up 2.15 percent on Thursday, January 17, 2019, on 88 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
|See historical VNDA trend table...|
|Date||Alert Name||Type||% Chg|
|Jan 17||Multiple of Ten Bullish||Other||0.00%|
|Jan 17||Wide Bands||Range Expansion||0.00%|
|Jan 17||Overbought Stochastic||Strength||0.00%|
|Jan 17||Up 3 Days in a Row||Strength||0.00%|
|Jan 16||Pocket Pivot||Bullish Swing Setup||2.15%|
|Jan 16||Multiple of Ten Bullish||Other||2.15%|
|Jan 16||Overbought Stochastic||Strength||2.15%|
|Jan 15||180 Bullish Setup||Bullish Swing Setup||5.22%|
|Jan 15||Outside Day||Range Expansion||5.22%|
|Jan 15||Overbought Stochastic||Strength||5.22%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Vanda Pharmaceuticals, Inc., a biopharmaceutical company, offers development and commercialization of products for the treatment of central nervous system disorders. The company provides Fanapt, a compound for the treatment of schizophrenia; and VLY-686, a small molecule neurokinin-1 receptor (NK-1R) antagonist that has indications for chemotherapy-induced nausea and vomiting, post-operative nausea and vomiting, alcohol dependence, anxiety, depression, and pruritus. Its product in clinical development includes Tasimelteon, which completed Phase III clinical trials for the treatment of circadian rhythm sleep disorders, as well as completed Phase IIb/III trials for the treatment of major depressive disorder and insomnia. Vanda Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Washington, District of Columbia.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more VNDA news...
|52 Week High||33.44|
|52 Week Low||13.88|
|200-Day Moving Average||20.7405|
|50-Day Moving Average||25.73|
|20-Day Moving Average||27.1565|
|10-Day Moving Average||28.993|
|Average True Range||1.384|
|Chandelier Exit (Long, 3 ATRs )||26.908|
|Chandelier Exit (Short, 3 ATRs )||27.322|
|Upper Bollinger Band||31.2848|
|Lower Bollinger Band||23.0282|
|Percent B (%b)||0.94|
|MACD Signal Line||0.9603|
|Market Cap||1.38 Billion|
|Num Shares||44.9 Million|
|Price-to-Earnings (P/E) Ratio||-134.00|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||33.00|
|Resistance 3 (R3)||32.83||31.95||32.63|
|Resistance 2 (R2)||31.95||31.39||32.03||32.51|
|Resistance 1 (R1)||31.38||31.05||31.67||31.55||32.39|
|Support 1 (S1)||29.93||29.94||30.22||30.10||29.25|
|Support 2 (S2)||29.05||29.60||29.13||29.13|
|Support 3 (S3)||28.48||29.05||29.01|
|Support 4 (S4)||28.65|